Mangoceuticals (MGRX) versus Its Rivals Head to Head Review

Mangoceuticals (NASDAQ:MGRX) is one of 21 publicly-traded companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it contrast to its rivals? We will compare Mangoceuticals to related companies based on the strength of its valuation, analyst recommendations, institutional ownership, profitability, dividends, earnings and risk.

Earnings and Valuation

This table compares Mangoceuticals and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mangoceuticals	$730,000.00	-$9.21 million	-0.35
Mangoceuticals Competitors	$2.35 billion	$61.83 million	14.04

Mangoceuticals’ rivals have higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations and price targets for Mangoceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	0	0	0	0	N/A
Mangoceuticals Competitors	39	311	467	149	2.75

As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 53.30%. Given Mangoceuticals’ rivals higher possible upside, analysts plainly believe Mangoceuticals has less favorable growth aspects than its rivals.

Profitability

This table compares Mangoceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-1,053.93%	-243.34%	-200.73%
Mangoceuticals Competitors	-742.79%	-44.75%	-34.16%

Volatility and Risk

Mangoceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Mangoceuticals’ rivals have a beta of 3.69, suggesting that their average stock price is 269% more volatile than the S&P 500.

Institutional and Insider Ownership

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 61.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 39.3% of Mangoceuticals shares are held by insiders. Comparatively, 28.0% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Mangoceuticals rivals beat Mangoceuticals on 9 of the 10 factors compared.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.